Appendix 4E and Annual Report
Filed with ASX · · 48 pages · English and French
Summary by 6ix AI
The report indicates a slight increase in revenues, but the company recorded a significant loss attributable to its owners. No dividends were declared or paid during the financial period, reflecting the company's ongoing investment in its operations. The report also highlights a strategic transition within the company, focusing on commercial execution and operational improvements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Australian patent for PromarkerEndo
- Proteomics signs national distribution deal with Healius
- US patent secured for PromarkerEndo
- Proteomics Strategic Plan
- Restructure, Executive Appointment and Board Update
Later from Proteomics International Laboratories
- PromarkerD and PromarkerEso Commercial Rollout Update
- PromarkerEndo Validation and Refinement Complete
- Proteomics International receives $2.0m in R&D tax incentive
- National Rollout of PromarkerD and PromarkerEso
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories